The androgen receptor (AR) is a ligand-activated transcription factor that drives prostate cancer. Since therapies that target the AR are the mainstay treatment for men with metastatic disease, it is essential to understand the molecular mechanisms underlying oncogenic AR signaling in the prostate. miRNAs are small, non-coding regulators of gene expression that play a key role in prostate cancer and are increasingly recognized as targets or modulators of the AR signaling axis. In this review, we examine the regulation of AR signaling by miRNAs and vice versa and discuss how this interplay influences prostate cancer growth, metastasis and resistance to therapy. Finally, we explore the potential clinical applications of miRNAs implicated in the regulation of AR signaling in this prevalent hormone-driven disease.
Introduction
The androgen receptor (AR) signaling axis is critical for normal prostatic development and maintenance and is the major driver of prostate cancer (PCa) growth and disease progression. Androgens such as testosterone and its more active metabolite, dihydrotestosterone (DHT), bind to the AR in the cytoplasm of prostate epithelial cells, which elicits its translocation into the nucleus. Ligand-activated AR binds to specific DNA sequences termed AR response elements (AREs) in regulatory regions of target genes, resulting in transcriptional activation or, less commonly, repression (Wang et al. 2009 ). In normal prostate epithelial cells, a key function of AR target genes is to maintain luminal differentiation; by contrast, in malignant prostate cells an aberrant AR transcriptional program promotes cell proliferation and survival (Coutinho et al. 2016) .
Given the critical role of AR in PCa, androgen deprivation therapy (ADT) is the primary treatment for metastatic disease (Feldman & Feldman 2001) . ADT encompasses multiple agents that: (i) decrease circulating androgen levels by inhibiting pituitary signals that stimulate testicular androgen production, i.e. lutenizing hormone-releasing hormone (LHRH) and gonadotropinreleasing hormone (GnRH) agonists; (ii) diminish biosynthesis of androgens, i.e. inhibitors of androgen biosynthetic enzymes; and/or (iii) inhibit AR activity i.e. agents that block androgen binding to the AR, termed AR antagonists. Unfortunately, these treatments inevitably fail, normally after a period of 2-3 years. The resultant disease is termed castration-resistant prostate cancer (CRPC) (Scher et al. 2004) . AR remains the key driver of most cases of CRPC. Maintenance of AR activity despite low levels of circulating androgens can be achieved through amplification or mutation of the AR gene, alternative splicing to produce constitutively active AR splice variants, altered expression of AR co-regulators and/or enhanced intra-tumoral androgen production (Coutinho et al. 2016) .
miRNAs are a class of small non-coding RNAs, approximately 22 nt in length, that post-transcriptionally silence target mRNAs. An estimated 60% of all proteincoding mRNAs are targeted by miRNAs (Friedman et al. 2009 ), highlighting the powerful influence these small transcripts can have on the transcriptome and how it is interpreted by the cell. Primary transcripts of miRNA genes (pri-miRNAs), transcribed primarily by RNA polymerase II, can be encoded by sequences within (intragenic) or outside of (intergenic) protein-coding genes (Lee et al. 2004 , Rodriguez et al. 2004 . Following transcription of a miRNA gene (or host gene), pri-miRNAs are processed into precursor miRNAs (pre-miRNAs) that fold into a stem loop structure and are exported from the nucleus (Kim 2005) . Within the cytoplasm, pre-miRNAs are cleaved into a miRNA duplex that is then separated; one strand is the final mature form of approximately 22 bp and the other strand is degraded (Kim 2005) . As part of the RNA-induced silencing complex (RISC) that includes Argonaute (Ago) proteins, miRNAs bind to target mRNAs and promote transcript degradation and/or translational inhibition (Fabian & Sonenberg 2012) . miRNAs generally bind to the 3′UTR of their target genes through complementarity with a region called the seed sequence, consisting of nucleotides 2-8 on the 5′ to 3′ ends of a miRNA sequence (Lewis et al. 2005) , although an increasing number of studies have also identified functional miRNA recognition sites in the coding and 5′UTR regions of genes (Brummer & Hausser 2014 , Zhou & Rigoutsos 2014 , Ito et al. 2017 .
Dysregulated miRNA expression is a hallmark of cancer development and metastasis (Calin & Croce 2006 , Jackson et al. 2014 . PCa-associated miRNAs were initially reported by Porkka and colleagues who identified differential expression of miRNAs between benign and malignant prostatic tissue (Porkka et al. 2007) . miRNAs have since been implicated in all aspects of prostate carcinogenesis and progression to metastatic and therapyresistant disease , Luu et al. 2017 . Moreover, since some PCa-associated miRNAs exist stably in the circulation of patients, there is considerable interest in their utility as blood-based biomarkers to improve PCa diagnosis, prognosis and treatment management (Fabris et al. 2016 , Kanwal et al. 2017 , Matin et al. 2018 .
In this review we explore the significance of the interplay between the AR signaling axis and miRNAs as it relates to PCa growth and progression. Finally, we speculate on the potential clinical applications of miRNAs implicated in the regulation of AR.
Regulation of AR by microRNAs

Direct targeting of AR by miRNAs
Mechanisms by which miRNAs influence the AR signaling axis are depicted in Fig. 1 . One prominent feature of this interplay is direct targeting of the AR 3′UTR by miRNAs. Indeed, a recent study predicted that the AR 3′UTR is likely to be more heavily regulated by miRNAs than all other PCa driver genes and in the top 5% of regulated genes overall (Hamilton et al. 2016) . This elegant work exploited photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein (Ago-PAR-CLIP) to identify 147 miRNA seed sides corresponding to 71 miRNA families in the AR 3′UTR (Table 1) . Importantly, four of the miRNAs identified by Hamilton and colleagues -miR-9, miR-34c, miR-185 and miR-488 -had been previously discovered in two highthroughput screens aimed at identifying AR-targeting miRNAs (Östling et al. 2011 (Östling et al. , Kumar et al. 2016 (Table 1 ). In addition to these unbiased approaches, many other studies have characterized specific AR-targeting miRNAs in a more directed manner. Interestingly, in addition to classical targeting of the 3′UTR, miRNA regulation of the AR via 5′UTR (miR-31) and the coding region (miR-421, miR-449a, miR-449b, miR-646, miR-371, miR-193a and miR-9) has also been reported (Östling et al. 2011 , Lin et al. 2013 , Kumar et al. 2016 . A list of putative AR-targeting miRNAs and their putative modes of action is provided in Table 1 .
We propose that the biological relevance of these AR-targeting miRNAs can be prioritized using a set of discrete parameters. First, miRNAs that have been identified in multiple studies using multiple in vitro models are likely to have greater biological relevance in PCa. Second, it is known that transfection of cells with miRNA mimics can yield non-physiological miRNA activity; therefore, we prioritize studies that have demonstrated AR targeting using both miRNA mimics and inhibitors. Third, given that prostate tumors are 'addicted' to AR (Coutinho et al. 2016) , one would expect oncogenic selection pressure to downregulate biologically relevant AR-targeting miRNAs. Indeed, a number of AR-targeting miRNAs have been reported to be downregulated in prostate tumors compared to non-malignant prostate tissues. However, it is worth noting that our own analyses of miRNA expression in The Cancer Genome Atlas (TCGA) and Memorial Sloan-Kettering Cancer Center (MSKCC) (Taylor et al. 2010 ) often contradict the published associations with cancer ( Fig. 2A and B ). Finally, it would be expected that biologically relevant miRNAs are inversely correlated with AR protein levels in clinical samples. Indeed, our analysis of the TCGA cohort revealed such a correlation for miR-145, miR-205, miR-34a and miR-31 ( Fig. 2C ). Using these parameters for prioritization and taking into account both published findings and our new analyses, we have generated a list of candidate AR-targeting miRNAs shown in Table 2 , which are ranked by predicted relevance in PCa. We propose that downregulation of at least a subset of these miRNAs is a key enabler of enhanced AR expression and activity in this disease.
When considering targeting of AR by miRNAs, it is worth noting that the reference AR 3′UTR sequence is annotated as being 6777 nucleotides in length (NM_000044.4), but other isoforms have been reported. For example, LNCaP cells have been reported to express an AR isoform with the canonical ~6.8 kb 3′UTR and another alternatively spliced version that lacks a 3 kb region in the 3′UTR (Faber et al. 1991) . Moreover, Ostling and colleagues delineated a 6680 nucleotide AR 3′UTR in VCaP cells, a sequence that was also identified in LNCaP, LAPC-4, 22Rv1 and MDA-PCa-2b cell line models (Östling et al. 2011) . In addition to variation in length, five SNPs were identified in the AR 3′UTR in PCa cell lines (Waltering et al. 2006) . Interestingly, SNPs have been reported to influence miRNA targeting of multiple genes in PCa (Stegeman et al. 2015a,b) , although our analyses indicate that none of the AR 3′UTR SNPs occur within conserved miRNA recognition sequences (not shown). Nevertheless, we believe that reported variations in the length and sequence of the AR 3′UTR warrants further consideration in relation to interplay with miRNAs, especially since 3′UTR sequences are often overlooked in genomic and transcriptomic studies.
Direct targeting of AR splice variants by miRNAs
AR splice variants (ARVs) are truncated isoforms of the AR that lack part or all of the C-terminal ligand-binding domain (LBD) (Antonarakis et al. 2016) . ARV mRNAs were first identified in PCa cell lines (Dehm et al. 2008 , Guo et al. 2009 ) but have since been detected in patient specimens including primary tumors and metastases, circulating tumor cells and whole blood (Hu et al. 2009 , Hornberg et al. 2011 , Antonarakis et al. 2014 . Recent RNA-seq data indicate the presence of at least 16 distinct ARV mRNA species in primary PCa (Cancer Genome Atlas Research Network 2015) and 23 in metastatic CRPC (Robinson et al. 2015) . A subset of these ARVs are constitutively active (i.e. they can regulate transcription in the absence of androgen) and are therefore resistant to therapies that target the LBD (Chan et al. 2015) . Although the relevance of ARVs in driving the growth of CRPC remains to be definitively proven (Luo et al. 2018) , it is worth noting that high expression of certain ARVs, such as AR-V7 and AR-V9, correlates with resistance to AR-targeted therapies and worse survival (Qu et al. 2015 , Kohli et al. 2017 , He et al. 2018 . Given the clinical relevance of ARVs, it is important to understand how they are regulated by miRNAs in PCa. Of note, ARVs possess 3′UTR sequences distinct from the canonical AR transcript (Hu et al. 2011 , Shi et al. 2015 ( Fig. 3A ). Recent studies have begun to decipher miRNA regulation of ARVs. Interestingly, a number of miRNAs regulate both canonical AR and specific ARVs through different target sites. For example, miR-124 targets the AR transcript via a 3′UTR site that is distinct from another functional targeting site in the 3′UTRs of AR-V3, AR-V4 and AR-V7 ( Fig. 3B) (Shi et al. 2013 , Shi et al. 2015 . Although the complete repertoires of ARV-targeting miRNAs remain to be determined, the identification of miRNAs that target both AR and ARVs via distinct sequences is intriguing and may suggest co-evolution of miRNAs and alternative AR splicing. Another mechanism by which miRNAs target both AR and ARV transcripts is via shared sequences in coding regions, as exemplified by translational regulation of AR and AR-V7 by miR-646, miR-371-3p and miR-193a-3p (Kumar et al. 2016) . Importantly, differences in the 3′UTRs of ARVs and AR suggest that many of the identified AR-targeting miRNAs would not influence ARV expression and vice versa. While this remains to be proven for most miRNAs, a recent study provided proof of concept by showing that miR-181c-5p effectively suppresses AR-V7 expression by 
Figure 2
Expression of putative AR-targeting miRNAs in clinical samples. (A) Expression of putative AR-targeting miRNAs in matched normal and primary prostate cancers from The Cancer Genome Atlas (TCGA). TCGA miRNA expression data were obtained from Genomic Data Commons, which uses miRBase v21 as miRNA reference; miRNA names were derived miRBase v21 and converted where necessary. miRNA abundance (reads-per-million-miRNA-mapped) was calculated by taking the sum of all counts per miRNA (unique MIMAT ID), and the MIMAT ID was then converted to its appropriate miRNA name. Only miRNAs that were expressed in more than 50% of samples were included in this analysis. P values were determined using paired t tests; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (B) Expression of putative AR-targeting miRNAs in normal and prostate cancer (primary and metastatic) in the Memorial Sloan-Kettering Cancer Center (MSKCC) cohort. Normalized miRNA expression data for the MSKCC cohort was obtained from cBioPortal (www. cbioportal.org). P values were determined using unpaired t tests; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (C) Correlation between putative AR-targeting miRNAs and AR protein levels in the TCGA cohort. AR protein levels are from reverse phase protein array data, obtained from the Broad Institute's GDAC Firehose. RPPA data were available for 145 primary prostate tumors. Only AR-targeting miRNAs that exhibited a significant (P < 0.05) negative Pearson correlation with AR protein levels in these 145 tumors are shown.
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Endocrine-Related Cancer Endocrine-Related Cancer targeting its 3′UTR but has no effect on the levels of the prototypical AR (Wu et al. 2019) . Interestingly, AR-V7 and ARv567es exhibit greater post-transcriptional stability than AR in CRPC bone metastases (Hornberg et al. 2011) ; it is tempting to speculate that this may be (at least partly) explained by differential miRNA targeting.
Indirect modulation of AR expression and activity by miRNAs
As well as direct regulation of AR, miRNAs can indirectly influence the expression and activity of AR via multiple mechanisms (Fig. 1) , including targeting AR co-regulators. Approximately 200 AR co-regulatorsbroadly classified as co-activators and co-repressors -have been identified, comprising a highly complex and potent system for shaping AR function in PCa ).
The co-repressor small heterodimer partner (SHP) is downregulated by miR-141, which is frequently elevated in PCa, thereby indirectly contributing to activation of AR's transcriptional activity (Xiao et al. 2012) . Another AR corepressor, prohibitin (PHB), is targeted by miR-27a, leading to increased expression of AR target genes and PCa cell growth (Fletcher et al. 2012) . Interestingly, miR-27a is an androgen-regulated miRNA, creating a feedback loop that represents a novel mechanism by which AR enhances its own activity. Concomitant with enhanced miRNA-mediated targeting of AR co-repressors in PCa is the frequent loss or downregulation of miRNAs that target AR co-activators. For example, miR-137 targets a suite of AR co-activators and is progressively lost with tumor grade due to DNA methylation of the MIR137 locus (Nilsson et al. 2015) . Loss of miR-331-3p, which targets the ERBB2 (HER2) oncogene, another AR co-activator (Craft et al. 1999) , also enhances AR signaling in PCa (Epis et al. 2009 ). The AR co-activators p300/CBP-associated factor and bromodomain-containing 8 isoform 2 are targeted by miR-17-5p and miR-185, respectively, leading to reduced AR transcriptional activity in PCa cells (Xiao et al. 2012 , Jiang et al. 2016 . Interestingly, miR-185 also directly targets AR, enabling this miRNA to mediate a dual mode of inhibition of the AR signaling axis (Jiang et al. 2016) .
Another mechanism by which miRNAs indirectly influence the AR signaling axis is by targeting factors that regulate AR gene expression. For example, miR-let-7c targets the oncogenic transcription factor Myc, thereby indirectly downregulating AR expression (Nadiminty et al. 2012) . Similarly, by directly targeting fibronectin type III domain-containing 1, miR-1207-3p reduces fibronectin 1 and subsequently AR expression (Das et al. 2016 ). Todorova and colleagues reported that miR-204 targeting of the DNA methyltransferase DNMT1 results in decreased methylation of, and hence, increased transcription from, the AR gene promoter (Todorova et al. 2017) . The nuclear matrix protein hnRNPH1, which is upregulated in prostate tumors and promotes the expression of AR and AR-V7, AR transactivation and binding to AREs, is a target of miR-212 ; miR-212 is downregulated in prostate tumors and its ectopic expression in PCa cell lines results in decrease in hnRNPH1 and AR expression . In summary, targeting AR co-regulators and upstream regulators of AR expression allows miRNAs to exert an additional layer of regulation on this key oncogenic signaling axis (Fig. 1 ).
Regulation of microRNAs by the AR signaling axis Direct regulation of miRNA gene expression by AR
The AR can directly regulate the PCa 'miRNAome' by binding to androgen response elements (AREs) within cisregulatory regions that regulate miRNA gene expression (Fig. 4) . The integration of AR genome-wide DNAbinding profiles ('cistromes') with androgen-regulated transcriptomes has greatly facilitated the identification of direct miRNA target genes (e.g.; Takayama et al. 2011 , Pasqualini et al. 2015 . This strategy has been used successfully irrespective of whether miRNAs are encoded in an intragenic or intergenic manner (Pasqualini et al. 2015) . In general, AR induces oncogenic miRNAs, which act as downstream effectors of AR signaling, and represses tumor suppressor miRNAs (Table 3) , although exceptions to this rule exist (see paragraph immediately below). Key oncogenic miRNAs that are directly upregulated by AR's transcriptional activation function include miR-19a, miR-27a, miR-133b and miR-185-5p, all of which can promote PCa cell growth and/or survival (Mo et al. 2013 , Yao et al. 2016 , whereas tumor suppressor miRNAs directly repressed by AR include miR-221/222 and miR-421 (Meng et al. 2016 .
While AR is the major driver of PCa, it also plays an essential role in normal prostate physiology, where it primarily regulates a differentiative rather than proliferative transcriptional program (Coutinho et al. 2016) . This concept may explain the observation that AR also promotes the expression of miRNAs that inhibit Key mechanisms by which AR controls the miRNAome in prostate cancer, including direct regulation of miRNA expression (1), regulating epigenetic machinery that modulates expression of miRNAs (2) and regulating the expression and activity of the miRNA biogenesis machinery (3).
proliferation (e.g. miR-101, miR-135a and miR-1, which target the oncogenic factors EZH2, ROCK1/2 and SRC respectively; Cao et al. 2010 , Kroiss et al. 2015 and promote epithelial differentiation (e.g. miR-200b, which targets factors that drive epithelialmesenchymal transition, such as ZEB1; Williams et al. 2013) .
Indirect regulation of miRNA expression and/or activity by the AR signaling axis
Indirect regulation of miRNAs by the AR can occur through a variety of mechanisms (Fig. 4) . First, AR appears to play an important regulatory role in miRNA biogenesis (Fletcher et al. 2012 ) by upregulating expression of DICER (Mo et al. 2013) and also, at least for certain miRNA transcripts, modulating the activity of Drosha (Fletcher et al. 2012) . The latter mechanism was elegantly elucidated by Fletcher and colleagues who demonstrated a dual mode by which AR regulates miR-27a: AR induced the expression of the primiR-23a27a24-2 cluster and concomitantly accelerated Drosha-mediated processing of this cluster to generate mature miR-27a (Fletcher et al. 2012) . The biological significance of AR's role in regulating the PCa miRNAome was highlighted by the observation that treatment of LNCaP cells with the AR antagonist enzalutamide results in a ~25% reduction in the number of miRNAs associated with gene 3′UTRs (Hamilton et al. 2016) . AR-mediated regulation of the epigenomemore specifically, interplay between the AR and DNA methylation machinery -also modulates miRNA expression. As an example, by negatively regulating DNMT1, AR elicits hypomethylation and activation of the MIR375 promoter (Chu et al. 2014) . Similarly, AR appears to regulate the DNA methylation levels of genomic elements that regulate the expression of miR-22 and miR-29a, although the mechanism by which it achieves this is unclear (Pasqualini et al. 2015) .
Androgen receptor-mediated rewiring of microRNA/mRNA transcriptional networks
The androgen-regulated transcriptome has been examined in many different PCa models and contexts (Nelson et al. 2002 , Velasco et al. 2004 , Ngan et al. 2009 , Massie et al. 2011 , Pomerantz et al. 2015 . However, it is often difficult to identify which of these transcripts are directly regulated by AR, largely due to the fact that AR often binds to enhancers that are distal to its target genes (Wang et al. 2007) . Carefully assessing the temporality of androgenmediated gene regulation (Massie et al. 2011) , integrating transcriptomic data with AR cistromes (Pomerantz et al. 2015) and/or using more sophisticated transcriptomic techniques such as global run-on sequencing (GRO-seq) (Toropainen et al. 2016) , which is designed to identify nascent transcription, have improved the detection of bona fide AR targets in PCa cell lines and tissues. Nevertheless, accurately differentiating direct vs indirect targets of the AR remains challenging.
We propose that indirect regulation of proteincoding genes by androgens/AR is heavily influenced by the same genes being direct targets of AR-regulated miRNAs. Sun and colleagues explored this concept by evaluating the AR-repressed miR-99a/let7c/125b-2 cluster and discovered significant enrichment of AR-induced genes that are putative targets of these miRNAs . Importantly, this in silico finding was validated for select candidate targets of each miRNA . We have expanded on this earlier work by intersecting TargetScan-predicted targets (Agarwal et al. 2015) of AR-induced miRNAs with a panel of androgen-repressed genes, and vice versa (Massie et al. 2011) (Table 4) . Androgen-repressed genes are significantly over-represented in the putative targets of certain AR-induced miRNAs, whereas androgen-induced genes are over-represented in the targets of certain AR-repressed miRNAs. Our analysis provides strong evidence that protein-coding genes can be regulated by AR signaling via AR-mediated rewiring of miRNA/mRNA transcriptional networks. This phenomenon should be considered when undertaking genomic analysis of AR activity as it may facilitate the elucidation of direct vs indirect transcriptional regulation.
Regulation of AR and miRNA expression by feedback loops
Feedback loops are a common feature of the interplay between AR and miRNAs. For example, the MIR21 gene is directly activated by the AR; conversely, miR-21 increases expression of AR in PCa cell lines, potentially by targeting PTEN -although the precise mechanism remains unclear (Ribas et al. 2009 , Mishra et al. 2014 ). Since miR-21 potently stimulates prostate tumor growth and metastasis, this feedback loop is likely to play a key role in PCa progression by maintaining expression and activity of 2 oncogenic factors (i.e. AR and miR-21) , Reis et al. 2012 , Bonci et al. 2016 . Conversely, the AR-repressed miRNAs miR-31 and miR-421 both target the AR directly (Östling et al. 2011 , Lin et al. 2013 , Meng et al. 2016 ). In the case of miR-31, this negative feedback loop is shifted in favor of the AR during disease progression, since DNA hypermethylation and subsequent downregulation of miR-31 is a feature of aggressive prostate tumors (Lin et al. 2013 , Meng et al. 2016 .
Indirect regulatory loops between miRNAs and the AR also exist. For example, miR-190a is directly repressed via an AR-binding site in its promoter, and in turn it suppresses AR expression and activity by targeting the 3′UTR of YB1 (Xu et al. 2015) , a transcription factor that acts to enhance AR gene transcription and also as an AR co-activator (Shiota et al. 2011 .
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miRNAs as regulators of therapy resistance in prostate cancer
A key feature of CRPC is the acquisition of miRNA activity that promotes cell survival in androgen-depleted conditions. Given the central role of AR in CRPC, it is not surprising that many of these miRNAs act, at least in part, by enhancing AR expression and/or activity. The feedback loop between miR-21 and AR has already been described earlier; in the context of CRPC, it is worth noting that overexpression of miR-21 alone is sufficient to impart androgen-independent growth (Ribas et al. 2009 ). Unlike miR-21, miR-221/22 is repressed by AR signaling; however, it plays a similar role in promoting CRPC growth: upon castration, it is immediately upregulated and acts to enhance the expression of key cell cycle genes . Another example of a CRPC-relevant miRNA that influences AR is miR-125b, which was found to be elevated in androgen-independent derivatives of the LNCaP model (Shi et al. 2007 ). By targeting the AR co-repressor NCoR2, miR-125b enhances AR signaling and thereby promotes androgen-independent growth (Yang et al. 2012) . Concomitant with gain of oncomiRs in CRPC is loss of miRNAs that inhibit survival, proliferation and other oncogenic properties, including miR-146a, which targets the oncogene Rho-activated protein kinase (Lin et al. 2007 (Lin et al. , 2008 ; let-7c, which targets the oncogenes Myc and Lin28 (Nadiminty et al. 2012) ; miR-145-3p, which targets cell cycleassociated genes ) and the AR-targeting miRNAs miR-30c-5p and 30d-5p (Kumar et al. 2016) .
While the aforementioned miRNAs appear to play important roles in the progression of PCa to a castration-resistant state, it is noteworthy that studies evaluating expression of miRNAs in CRPC tissues are poorly concordant. Nevertheless, by comparing miRNAs putatively associated with CRPC in three published genome-wide miRNA profiling studies (Jalava et al. 2012 , Goto et al. 2015 and combining this with our own analysis of the Memorial Sloan-Kettering Cancer Center cohort (Taylor et al. 2010) , we have identified a set of miRNAs that are reproducibly dysregulated in CRPC ( Table 5 ). miRNAs that were not reproducibly altered in these studies may be false positives or alternatively may simply reflect differences in experimental design; for example, one study compared miRNA expression between benign prostatic hyperplasia and CRPC (Jalava et al. 2012) , while the others compare normal prostate tissues or hormone-naïve PCa with CRPC (Taylor et al. 2010 , Goto et al. 2015 . Moreover, only the latest of these employed RNA-seq , while the earlier studies used PCR arrays (Goto et al. 2015) or miRNA microarrays (Taylor et al. 2010 , Jalava et al. 2012 .
Clinical potential of AR-associated microRNAs in prostate cancer
AR-associated miRNAs as biomarkers
Circulating miRNAs can be detected in many body fluidsmost notably serum, plasma and urine -and have shown Agarwal et al. 2015) . b P values were calculated using hypergeometric probability tests. Genes in universe = 18,393 i.e. total number of genes in Targetscan database. AR-repressed genes (n = 436) and AR-upregulated genes (n = 625) are from Massie et al. (2011). promise as biomarkers for PCa diagnosis and prognosis and predicting therapy response. Since this topic has been comprehensively encapsulated in recent reviews (Fabris et al. 2016 , Kanwal et al. 2017 , here we will briefly touch on the relevance of the AR signaling axis to these putative biomarkers. Several PCa-associated circulating miRNAs are known to be regulated by AR, suggesting that -like the classic PCa marker prostate-specific antigen (Catalona et al. 1991 ) -their release into circulation is likely increased in PCa due to elevated AR activity. One prominent example is miR-375, which has consistently been identified as a potential marker of PCa, with higher levels in serum or plasma being associated with shorter overall survival and metastasis (Mitchell et al. 2008 , Brase et al. 2011 , Selth et al. 2012 , Huang et al. 2015 . AR indirectly promotes miR-375 transcription by suppressing DNA methylation of its promoter (Chu et al. 2014 ), and we have previously shown that miR-375 levels are positively correlated with androgen signaling in multiple tumor datasets (Selth et al. 2017) . The release of miR-375 from LNCaP cells into culture medium is stimulated by DHT (Tiryakioglu et al. 2013 , Gezer et al. 2015 , suggesting that its levels in the blood of patients would be increased in PCa due to elevated AR activity. Other AR-regulated miRNAs that Goto et al. (2015) , Goto et al. (2017 ) miR-24 Downregulated 4 Taylor et al. (2010 , Jalava et al. (2012) , Goto et al. (2015 Goto et al. ( , 2017 Upregulated 2 Table 5 if they were reproducibly altered in >50% of studies i.e. 3 out of 4; upregulated miRNA were listed if they were reproducibly altered in >50% of studies i.e. 2 out of 2 (Goto et al (2015 and only report miRNAs downregulated in CRPC, and were therefore excluded when identifying upregulated miRNAs). Comparisons were done between benign prostatic hyperplasia vs CRPC (Jalava et al. 2012) or both normal/primary vs CRPC (Taylor et al. 2010 , Goto et al. 2015 .
have been proposed as potential serum-or plasma-based biomarkers of PCa include miR-21 (Zhang et al. 2011 ), miR-125b (Fredsoe et al. 2018 , miR-141 (Gonzales et al. 2011 ), miR-19a (Stuopelyte et al. 2016 , miR-27a ) and miR-221/222 (Santos et al. 2014) .
Potentially the most useful application of circulating miRNAs would be in predicting response to therapies for CRPC. Given that an important subset of circulating miRNAs are AR regulated, it is conceivable that one or more of these may be useful in predicting response to AR-targeted therapies. Supporting this concept, elevated circulating miR-141 could predict clinical progression in a small cohort of CRPC patients with a sensitivity of 78.9% and specificity of 68.8%, although the therapies they received were mixed (chemotherapy, hormone therapy, or novel agents such as vaccines and kinase inhibitors) (Gonzales et al. 2011) . Additionally, high levels of miR-221 in peripheral blood are predictive of early CRPC development (Santos et al. 2014) . These examples suggest that circulating miRNAs could be useful additions to the biomarker armamentarium, although robust retrospective and prospective validation studies are required to move this field forward (Tavallaie et al. 2015 .
Exploiting AR-modulating miRNAs as a therapeutic strategy miRNA-based therapies are being actively pursued for a multitude of diseases, as eloquently described in several recent reviews (Hong et al. 2016 , Van der Ree et al. 2016 . In cancer, such therapies are focused on increasing levels of tumor suppressor miRNAs by delivery of miRNA mimics or decreasing levels of oncogenic miRNAs by delivery of antisense oligonucleotides (termed antimiRs or antagomiRs) (D'Angelo et al. 2016) . Since a single miRNA can regulate multiple cancer-related pathways, miRNAbased therapies possess considerable promise. However, like other nucleic acid-based strategies, issues related to stability in biofluids, delivery to the tissue of interest and toxicity of mimics and antimiRs have hindered their clinical development (Rupaimoole & Slack 2017) . While recent advances in formulation and delivery have led to miRNA-based therapies being tested in a range of clinical studies (Matin et al. 2016) , it is worth noting that none are yet used in the treatment of patients.
With these caveats in mind, the application of a miRNA-based therapy in PCa remains a distant goal. Nevertheless, it is clear that opportunities in this area exist, especially given the importance of the interplay between miRNAs and the AR. For example, miR-34a reduces PCa cell viability, at least in part by targeting AR (Östling et al. 2011) , but it also downregulates the expression of >30 oncogenes across multiple oncogenic pathways (Beg et al. 2017) . Cancer therapies based on master tumor suppressor miRNAs such as miR-34 are attractive because they would be expected to have high efficacy and at the same time reduce opportunities for resistance to develop. In pre-clinical studies, systemic delivery of a miR-34a mimic to mice harboring orthotopic PCa xenografts led to decreased tumor growth and metastasis (Liu et al. 2011) . A liposomal formulation of miR-34a, termed MRX34, was evaluated in a Phase 1 clinical trial of patients with primary liver cancer, advanced solid tumors and hematological malignancies. Unfortunately, this trial was terminated due to immune-related serious adverse side effects (Hong et al. 2016 , Van Roosbroeck & Calin 2017 . Nevertheless, the promising anti-tumor activity of MRX34 observed in a subset of patients (Beg et al. 2017 ) provides incentive to continue investigating miRNA-based therapies for cancer. Indeed, new strategies to more precisely deliver miRNAbased payloads to solid tumors are already showing promise: exciting findings from a recent phase I clinical trial in mesothelioma demonstrated that miR-16-loaded, EGFR-targeted 'minicells' demonstrated an acceptable safety profile and early signs of activity (van Zandwijk et al. 2017) .
As an alternative to therapies based on miRNA mimics or antimiRs, other strategies to regulate miRNA expression can be envisioned. Indeed, epigenetic therapies are being intensively investigated for a multitude of diseases, and we propose that an important aspect of their activity relates to miRNA biology. As specific examples associated with the AR signaling axis, re-activation of miR-124 using DNA demethylating agents or miR-320a with the histone deacetylase inhibitor OBP-801 lead to decreased AR expression and activity in PCa (Shi et al. 2013 , Sato et al. 2016 .
Summary
miRNAs and the AR are involved in an intricate dance mediated by direct interactions or complex indirect mechanisms involving transcription factors, co-regulators and epigenetic machinery (Figs 1 and 4) . Despite the complexity of this interplay, one overarching theme is that miRNAs play a major role in enhancing and maintaining AR activity throughout the course of PCa progression; miRNAs that antagonize AR expression and activity are frequently lost, whereas miRNAs that facilitate AR signaling are frequently gained. This phenomenon may be particularly relevant in CRPC, where miRNAs can play key roles in establishing and maintaining resistance to AR-targeted therapies. With this in mind, and given the continued focus on targeting AR in PCa, we propose that exploitation of miRNAs -potentially as biomarkers or therapeutic targets -warrants further consideration as a strategy to manage and/or treat this common disease. Finally, since AR is a key player and being investigated as a target in other solid tumors, including breast, bladder and hepatocellular, the value of understanding its interplay with miRNAs is increased; indeed, recent studies indicate that such interplay may be crucial to the progression of these other cancer types (Xiong et al. 2017 , Yang et al. 2018 ).
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